**Abstract**

Although COVID-19 was primarily considered a respiratory illness, rapidly accumulating data suggest that COVID-19 is associated with a high incidence of venous thromboembolic complications.

The primary objective of this review article was to reveal whether we need to increase awareness of pulmonary embolism in the period following the COVID-19 infection given that the epidemiologic facts are still poor.

A literature search and a critical review of the collected studies were conducted. An electronic search of PubMed, Science Direct Scopus, Google Scholar, and Excerpta Medica Database (EMBASE) from June 2020 until June 2022.

The long-term health consequences of COVID-19 remain largely unclear. This review highlights the importance of awareness of the potentially increased incidence of venous thromboembolism in post-COVID-19 patients, even those with mild or asymptomatic disease. Further research is required to establish appropriate clinical management guidelines for the prevention of thromboembolic complications in the post-COVID-19 period.

**Keywords** Pulmonary embolism · Post–COVID-19 · Thromboembolic events

**Introduction**

Coronavirus disease (COVID-19) is an infection caused by the novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)[1]. The clinical presentation of COVID-19 varies from mild to severe disease, provoking mild illness but also acute respiratory distress syndrome (ARDS), sepsis, as well as, multiorgan dysfunction[2]. Rapidly accumulating data suggest that COVID-19 is associated with coagulation abnormalities that increase the risk of both arterial and venous thromboembolic events (VTE)[3, 4]. The literature so far concerns studies that show an increased risk for thromboembolic events during COVID-19[5, 6]. In the literature, though, there are published data, mainly case reports that raise the red flag for a potentially increased risk of pulmonary embolism (PE) after COVID-19 infection[7]. This paper aims to discuss whether we need to increase awareness of post-COVID-19 PE. We will try to highlight the probability of PE after COVID-19 infection period.

**Database Search Strategy**

A critical literature review of the collected studies was conducted. An electronic search of PubMed, Science Direct Scopus, Google Scholar, and Excerpta Medica Database (EMBASE) from June 2020 until June 2022. A review of the titles and abstracts as well as a manual search of the reference lists were carried out.

**Epidemiology**

PE is a life-threatening manifestation of venous thromboembolism. Yearly, approximately 1 in 1000 persons suffers from PE worldwide[8, 9]. VTE is globally the third most frequent acute cardiovascular syndrome after myocardial infarction and stroke[10, 11]. COVID-19 is an ongoing
global public threat. As of December 20, 2021, the numbers of confirmed cases and confirmed deaths reported to World Health Organization (WHO) were 273,900,334 confirmed cases and 5,351,812 deaths[12]. It also is clear that the prevalence of PE during the COVID-19 pandemic is increased[13–16].

Pathophysiology

Over the past 2 years, data extracted from studies concerning COVID-19, imply the strong correlation between SARS-COV-2 infection and induced coagulopathy. The unique coagulation pattern and the high incidence of VTE in patients with COVID-19 suggest that different mechanisms, beyond the already known, are involved in the COVID-19 Associated Coagulopathy (CAC).

The predisposition for thrombosis in COVID-19 is driven by at least two distinct, but interrelated, processes. The first one includes mainly large-vessel occlusion, usually due to thromboembolism. The second one, which is the predominant theory, concerns microvascular in situ immunothrombosis, as a consequence of innate immune system activation[17]. The model of immunothrombosis involves the interplay of many pathways, among them, viral-mediated endothelial dysfunction and immune system dysregulation, leading to platelet and leukocyte activation and aggregation. Additional pathways taking part in CAC are cytokine cascade and complement activation[6]. Each of these pathways, that contributes the immunothrombosis, plays a pivotal role in the composition of CAC pathogenesis. However, unspecified pathophysiological mechanisms may contribute to the occurrence of thromboembolic events in the post-infectious period.

The first step of SARS-CoV-2 infection happens when the virus enters lung alveolar epithelial cells by the interaction between the viral surface S (spike) protein and angiotensin-converting enzyme 2 (ACE-2) receptor through processes involving cell surface-associated trans-membrane protein serine 2 (TMPRSS2)[18]. Then, it conducted a process including, RNA translation and replication, as well as protein synthesis. SARS-CoV-2 buds in the endoplasmatic reticulum — Golgi intermediate compartment (ERGIC) or Golgi apparatus and exits the cell via a biosynthetic secretory pathway[19]. Research suggests that SARS-CoV-2 has the potential to leave cells as small secretory vesicles that then release the virus[20]. Barberis et al. identified the presence of SARS-CoV-2 RNA in extracellular vesicles (EVs), suggesting that the virus may spread the infection through the endocytic route[21]. EVs are lipid bilayer membrane-bound structures released from leukocytes, mainly monocytes, under physiological and pathological conditions. Their function is to transport active components (such as DNA, mRNA, microRNA, and proteins) to nearby or distant cells to help maintain their physiological state[22]. The SARS-CoV-2 RNA can be hidden, transported, released by EVs, and re-attack various tissues and organs through the circulatory system. EVs may play a “Trojan horse” role in viral RNA reappearance in recovered COVID-19 patients[23]. This theory can be one of the potential mechanisms for the COVID-19 complications in the post-infection period. In addition to their function as transporters, EVs play an important role in inflammation, coagulation, and immune regulation. The released virus from EVs can provoke direct endothelial injury, in addition to preexisting endothelial dysfunction during the infectious period. The ROADMAP-post-COVID-19 study documents that endothelial cell activation and hypercoagulability up to 62 days from symptom onset is a common alteration in COVID-19 survivors[24]. As a consequence, tissue factor (TF) releases from the medial layers of the endothelium, promoting the activation of the extrinsic coagulation cascade. The endothelial injury leads to platelet activation, adhesion, and aggregation. Activated platelets and endothelium secrete protein disulfide isomerase (PDI) which activates microvesicle-derived TF (type of EVs), resulting in the release of TF, accelerating further the coagulation process[6]. The damaged endothelial cells induce a membrane’s molecule redistribution, leading to phosphatidylserine (PS) exposure in the outer cell membrane. PS is a membranous phospholipid normally sequestered in the inner leaflet of a cell membrane. PS exposure in the outer leaf of the cell membrane creates a catalytic surface for clotting factors which facilitate the conversion of prothrombin to thrombin[25]. Compared with patients without thrombosis, patients with thrombosis had significantly higher PS externalization[26]. Hence, the PS exposure due to viral infection may be another mechanism of coagulation activation[27]. The hypercoagulable state of COVID-19 is mainly due to a unique derangement in the hemostatic pathways. The presence of late thromboembolic events in the post-infectious period raises the scientists’ interest, in discovering the possible pathophysiological mechanism. A potential explanation is given by the EVs, which can carry the virus to distant tissues and various organs including the vascular system, re-injuring the vascular endothelium in the convalescent phase of COVID-19 infection. The expression of TF and PS exposure on the EVs surface are also important factors in promoting coagulation disorders. Consequently, the SARS-CoV-2 persistence due to EVs may stimulate the endothelial cells, platelets, and other inflammatory cells promote the upregulation of procoagulant factors, and destroys the protective function of vascular endothelium, thereby causing abnormal coagulation[25]. These may be potential mechanisms that can explain the residual thrombotic risk in post-COVID-19 patients.
Discussion — Thromboembolic PE in Post-COVID-19 Patients

In the previous paragraph, we summarized the pathophysiologic events that could explain PE late in the course of the disease or even after the infectious period. Also, the effects of persistent viral replication, inflammation, hypoxia, and endothelial injury leading to thrombosis and organ dysfunction in the long COVID could also explain the late PE[28]. Reviewing the literature, though, only a few data from small studies or case reports support the increased risk of PE after COVID-19 infection. The initial reports pinpointing a high incidence of 27–30% [29, 30] of PE in patients with COVID-19 were followed by numerous data questioning the number mentioned above. We have also considered the difficulty of interpreting the high incidence of PE in critically ill patients that are by default a high-risk group[31]. A recent meta-analysis highlights the fact that the actual incidence of thromboembolic episodes during COVID-19 remains unclear, while at the same time the PE is more frequent in Intensive Care Unit (ICU) admitted patients[32]. Another study has revealed a total 2.5% incidence of both arterial and venous thrombosis at day 30 following discharge and venous thromboembolism alone at 0.6%[14]. A meta-analysis from Kings College Hospital in London[15] has revealed among others that the patients hospitalized with COVID-19 do not have higher risk for thromboembolic disease after discharge in comparison with the patients that are hospitalized due to other acute diseases. It seems that the information derived from the studies fluctuates considerably and at the same time there is a clear lack of homogeneity in the patient group selected and followed, although all studies share the common interest in exploring the incidence of VTE and the need for thromboprophylaxis. Two more small studies seem also to agree that the incidence rate of VTE in the first 30–42 days after hospitalization due to COVID-19 is 0.6–0.48% [33, 34]. A retrospective multicenter study on consecutive COVID-19 patients hospitalized at 7 Italian hospitals showed an association between late hospitalization and PE in COVID-19 that could possibly be explained by the longer bed rest, delayed anticoagulant prophylaxis administration as well as the pathophysiologic mechanism involved in the later phases of COVID-19, characterized by the interplay between systemic hyper-inflammation state[35], immuno-mediated phenomenon and clotting system activation[36, 37]. In the same study, most PE were confirmed within 24 h after admission, suggesting that VTE was unrelated to hospitalization; probably, PE in COVID-19 is a progressive pathological process that begins in the early infection stage and manifests clinically in the late infectious phase leading to hospitalization later in the course of the disease[34]. The majority of the studies mentioned above refer to hospitalized patients that have been followed post-discharge from the hospital or are hospitalized. Not much is known though about the incidence of PE following a mild or uncomplicated or even asymptomatic COVID-19 infection. Our intention with this paper was to gather all the literature data including case reports in order to take a closer look at the patients, the course of their disease while COVID-19 positive and their presentation with VTE during post-COVID-19 period. Having said that, we wanted to show that even patients with mild COVID-19 infection might have increased risk for VTE after the infectious period. Data from case report studies describing PE in 52 patients at least 7 days after manifestation of COVID-19 infection were also taken into consideration. In Table 1, we summarize 52 reported cases, with an event of pulmonary embolism after COVID-19 infection. The minimum reported days after diagnosis is 7 days and the maximum is 180 days (mean 35.1 days) which agrees with the results of ROADMAP-post-COVID-19 study, documenting hypercoagulability up to 62 days[24]. The majority of the cases the time of clinical manifestation of PE is during the first month following the COVID-19 infection. In 40 cases out of 52, PE occurred in less than 36 days after infection. The majority of the patients were not under anticoagulation treatment mainly due to the fact that they manifest just mild disease during the infection. Namely, 32 cases didn’t need hospitalization or were asymptomatic during COVID-19 infection. Two patients were under Low Molecular Weight Heparin (LMWH)[33] and one under oral anticoagulants[41]. The cases concern almost equally patients in the 4th, 5th, and 6th decade of life. Although a tendency can be described, with the case reports, we still need more research or/and registries in order to have a clear view about the incidence of PE after COVID-19 infection and the time period where there is an increased risk for PE. That could actually raise a valid question, weather we need to add COVID-19 infection as an extra risk factor during assessment of the probability for manifestation of PE.

Conclusion

We reviewed the literature trying to answer whether we should increase awareness of PE during the post-COVID-19 period, especially for patients with asymptomatic or mild disease during the infection. Though we already know that the incidence of VTE is highest during the first 19 days after hospital admission[72] unfortunately, the duration of VTE risk in non-hospitalized patients or with short hospital stays remains unclear[73]. Knowing that COVID-19 increases the probability for a patient to have an event of PE, we
Table 1  Summarized 52 reported cases, with an event of pulmonary embolism after COVID-19 infection

| Pts               | G | Age yrs | Hospitalized during COVID-19 infection | Time between diagnosis of COVID19 and PE (days) |
|-------------------|---|---------|---------------------------------------|-----------------------------------------------|
| Bingwen Eug. Fan, 2021 [38] | 1 | M | 39 | No | 76 |
| Prakash Vaduluk, 2020 [39] | 1 | F | 52 | Yes | 30 |
| Abdoulaye Toure, 2020 [40] | 1 | F | 26 | Yes | 94 |
| Falmata L. Brem, 2021 [41] | 2 | M | 66 | Yes | 23 |
| Timothy Pow, 2021 [42] | 1 | M | 40 | No | 60 |
| Abdulrahman Al H., 2020 [43] | 2 | F | 50 | No | 20 |
| Franca Del Nonno, 2021 [44] | 1 | F | 61 | No | 35 |
| Muhanad Taha, 2021 [45] | 1 | M | 41 | No | 152 |
| Ayesha Jamil, 2021 [46] | 1 | F | 47 | No | 180 |
| Behshad N. Tabrizi, 2020 [47] | 1 | M | 68 | Yes | 14 |
| Falmata L. Brem, 2021 [48] | 3 | M | 68 | No | Not Known (Presence of IgG, IgM) |
| Phany B. I. Maloumbi, 2021 [59] | 1 | F | 38 | No | 17 |
| Emilia D’Elia, 2021 [49] | 1 | M | 51 | Yes | Not Known |
| J.C. Valencia M., 2021 [50] | 1 | F | 52 | Yes | 28 |
| Mohamad Kanso, 2020 [51] | 2 | M | 68 | Yes | 15 |
| Sadaf Ali, 2020 [52] | 1 | F | 52 | Yes | 25 |
| Mana Rahimzadeh, 2020 [61] | 1 | M | 61 | Yes | 36 |
| Gagan Kaur, 2021 [53] | 1 | M | 34 | No | 150 |
| Andrew Baird, 2021 [54] | 1 | F | 30 | No | 28 |
| Hareton T. Vechi, 2020 [55] | 5 | M | 63 | No | 23 |
| Calin Pop, 2021 [56] | 4 | M | 45 | Yes | 22 |
| Mats Beckman, 2020 [57] | 1 | M | 51 | No | 49 |
| Siri Overstad, 2020 [58] | 2 | M | 39 | No | 27 |
| Mario Karolyi, 2020 [60] | 4 | M | 45 | No | 21 |
| Mikkel Rodin Deutch, 2021 [62] | 2 | M | 87 | Yes | 24 |
| De Pace D, 2021 [63] | 1 | M | 72 | No | 90 |
| Ruba M. Barnawi 2022 [64] | 1 | M | 22 | No | 14 |
| Saída Amaqdouf, 2022 [65] | 1 | M | 92 | Yes | Unknown |
| Keerti Sitani, 2021 [66] | 1 | M | 41 | No | 30 |
| Tomasz Czerski, 2022 [68] | 1 | M | 49 | No | 20 |
Table 1 (continued)

|                                  | Pts | G | Age yrs | Hospitalized during COVID-19 infection | Time between diagnosis of COVID19 and PE (days) |
|----------------------------------|-----|---|---------|----------------------------------------|-----------------------------------------------|
| Kok Hoe Chan, 2021 [69]          | 2   | M | 65      | No                                     | 14                                            |
| Ersan Oflar, 2020 [70]           | 1   | M | 45      | Yes                                    | 7 (14 from symptoms)                          |
| Maria Ioannou, 2022 [71]         | 1   | M | 44      | Yes                                    | 27                                            |

anticipate that this will extend during the post-COVID-19 period[74]. There are only a few studies that managed to evaluate the incidence of VTE in post-Covd patients[33, 34]. Case reports data show that there is a wide range in the time frame between COVID-19 diagnosis and PE manifestation which need to be better understood. Additionally, it is still unclear whether PE following COVID-19 infection is a manifestation of the post-COVID-19 condition or not. The majority of case reports concerns patients that did not need hospitalization during the infection. It is necessary to define the critical time, following the resolution of COVID-19 during which patients are at high risk for developing PE. In conclusion, there is no hard evidence proving that a medical history of COVID-19 will increase the risk for PE but some indications that need to be further investigated. Further studies are needed to question a potential causal link between “post-COVID-19 PE” and preceding SARS-CoV-2 infection and to outline the high-risk period after the COVID-19 convalescence phase regardless of the severity of the infection.

Author contribution All authors contributed to the writing of this review.

Declarations

Ethics approval Fully compliant with ethical issues

Conflict of interest The authors declare no competing interests.

References

1. World Health Organization. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. 2021; [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)
2. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance. 2020; [https://apps.who.int/iris/handle/10665/331446](https://apps.who.int/iris/handle/10665/331446)
3. Abou-Ismail MY, Diamond A, et al. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thromb Res. 2020;194:101–15.
4. Giordano NJ, Jansson PS, et al. Epidemiology, pathophysiology, stratification, and natural history of pulmonary embolism. Tech Vasc Interv Radiol. 2017;20(3):135–40.
5. Price LC, McCabe C, Garfield B, Wort SJ. Thrombosis and COVID-19 pneumonia: the clot thickens?. Eur Respir J. 2020;56(1):2001608.
6. Jayarangaiah A, Kariyanna PT, et al. COVID-19-associated coagulopathy: an exacerbated immunothrombosis response. Clinical and applied thrombosis/hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2020;26 107629620943293
7. Vechi HT, Maia LR, Alves M. Late acute pulmonary embolism after mild coronavirus disease 2019 (COVID-19): a case series. Rev Inst Med Trop Sao Paulo. 2020;62: e63.
8. Lehneret P, Lange T, Møller CH, Olsen PS, Carlsen J. Acute pulmonary embolism in a national Danish cohort: increasing incidence and decreasing mortality. Thromb Haemost. 2018;118:539–46.
9. Payne JG, Tagalakis V, Wu C, Lazo- LA. Current estimates of the incidence of acute venous thromboembolic disease in Canada: a meta-analysis. Thromb Res. 2021;197:8–12.
10. Konstantinides SV, Meyer G. The 2019 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2019;40(42):3453–5.
11. Yevdokimova K, Poor HD. Pulmonary Thromboembolism in COVID-19. In: Herzog E (ed) Pulmonary Embolism. Springer, Cham. 2022.
12. World Health Organization. Covid-19-dashboard. 2022; [https://covid19.who.int/](https://covid19.who.int/)
13. Caplan ICU haemostasis COVID-19 group, Poissy J, Goutay J, Caplan M, et al. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation. 2020;142(2):184–6.
14. Patell R, Bogue T, Koshy A, et al. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood. 2020;136(11):1342–6.
15. Roberts LN, Whyte MB, Georgiou L, et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood. 2020;136(11):1347–50.
16. Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. JTH. 2020;20(6):1421–4.
17. Poor HD. Pulmonary thrombosis and thromboembolism in COVID-19. Chest. 2021;160(4):1471–80.
18. Vajari K, et al. COVID-19-related coagulopathy: a review of pathophysiology and pharmaceutical management. Cell Biol Int. 2021;45:1832–50.
19. V’kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and pathophysiology and pharmaceutical management. Cell Biol Int. 2021;45:1832–50.
20. Jayarangaiah A, Kariyanna PT, et al. COVID-19-associated coagulopathy: an exacerbated immunothrombosis response. Clinical and applied thrombosis/hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2020;26 107629620943293
21. World Health Organization. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. 2021; [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)
22. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance. 2020; [https://apps.who.int/iris/handle/10665/331446](https://apps.who.int/iris/handle/10665/331446)
21. Barberis E, et al. Circulating exosomes are strongly involved in SARS-CoV-2 infection. Frontiers in molecular biosciences. 2021;8:632290.

22. Karn Vamika, et al. Extracellular vesicle-based therapy for COVID-19: promises, challenges, and future prospects. Biomedicines. 2021;9(10):1373.

23. Borowiec BM, et al. Extracellular vesicles and COVID19—using the “Trojan horse” to tackle the giant. Cells. 2021;10(12):3383.

24. Gerotziafas GT, et al. Persisting endothelial cell activation and hypercoagulability after COVID-19 recovery—the prospective observational ROADMAP-Post COVID-19 study. Hematol. 2022;3(1):111–21.

25. Wang C, et al. Long COVID: the nature of thrombotic sequelae determines the necessity of early anticoagulation. Front Cell Infect Microbiol. 2022;12(861703):5.

26. Althaus Karina, et al. Antibody-induced procoagulant platelets in severe COVID-19 infection. Blood. 2021;137(8):1061–71.

27. Argáñaraz GA, Palmeira JF, Argáñaraz ER. Phosphatidylserine inside out: a possible underlying mechanism in the inflammation and coagulation abnormalities of COVID-19. Cell Commun Signal. 2020;18:190.

28. Wang C, Yu C, Jing H, Wu X, Novakovic VA, Xie R, Shi J. Long COVID: the nature of thrombotic sequelae determines the necessity of early anticoagulation. Front Cell Infect Microbiol. 2022;12:861703.

29. Léonard-Lorant I, Delabaranche X, et al. Acute pulmonary embolism in patients with COVID-19 at CT angiography and relationship to d-dimer levels. Radiology. 2020;296(3):E189–91.

30. Poyiadjii N, Cormier P, Patel PY, et al. Acute pulmonary embolism and COVID-19. Radiology. 2020;297(3):E335–8.

31. Kaplan D, Casper TC, Elliott CG, et al. VTE incidence and risk factors in patients with severe sepsis and septic shock. Chest. 2015;148(5):1224–30.

32. Suh YJ, Hong H, Ohana M, Bompad F, et al. Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis. Radiology. 2021;298(2):E70–80.

33. Engelen MM, Vandenbriele C, Balthazar T, et al. Venous thromboembolism in patients discharged after COVID-19 hospitalization. Semin Thromb Hemost. 2021;47(4):362–71.

34. Scudiero F, Silverio A, Di Maio M, et al. Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome. Thromb Res. 2021;198:34–9.

35. Siddiqui HK, Mehra MR. COVID-19 illness in native and immuno-suppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39(5):405–7.

36. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46–7.

37. Di Micco P, Russo V, Carannante N, et al. Clotting factors in patients with severe sepsis and septic shock. Chest. 2015;148(5):1224–30.

38. Fan BE, Umapathi T, Chua K, et al. Delayed catastrophic thrombotic events in young and asymptomatic post-COVID-19 patients. J Thromb Thrombolysis. 2021;51(4):971–7.

39. Vadukul P, Sharma DS, Vincent P. Massive pulmonary embolism following recovery from COVID-19 infection: inflammation, thrombosis and the role of extended thromboprophylaxis. BMJ case reports. 2020;10(9):e238168.

40. Abdoulaye Toure et al. Post-COVID-19 late pulmonary embolism in a young woman about a case. Open Journal of Emergency Medicine. 2020;

41. Brem FL, Missaoui Z, Aghal M, et al. Late-onset of pulmonary embolism following hospitalization for COVID-19 despite thromboprophylaxis: a report of two cases. Pan Afr Med J. 2021;38:226.

42. Pow T, Allen S, Brailovsky Y, Darki A. Acute submassive pulmonary embolism after SARS-CoV-2 infection: a case report of reinfection or prolonged hypercoagulable state. European heart journal Case reports. 2021;5(3):ytab103.

43. Alharya T, Balhamar A, Faqhi F, et al. Insidious development of pulmonary embolism in asymptomatic patients with COVID-19: two case reports. Respir Med Case Rep. 2020;31:101186.

44. Del Nonno F, Colombo D, Nardacci R, Falasca L. Fatal pulmonary arterial thrombosis in a COVID-19 patient, with asymptomatic history, occurred after swab negativization. Thromb J. 2021;19(1):1.

45. Taha M et al. Forty-one-year-old man with pulmonary embolism 5 months after COVID-19. Clin Med Insights Circ Resp Pulm Med. 2021. https://doi.org/10.1177/1179548420986659.

46. Jamil A, Shyam V, Neupane K. Atypical presentation of pulmonary embolism several months after COVID-19 infection. Cureus. 2021;13(1):e12863.

47. NamhseTabrizi B, Ghadimi Farah A, et al. Acute pulmonary embolism in post COVID-19 infection, A case report. ORLFPS. 2021;6(1):1–4.

48. LysanArem B, Rasras H, El Ouafi N, Bazid Z. Bilateral pulmonary embolism in patients recovered from asymptomatic COVID-19 infection. Cureus. 2021;13(3):e13848.

49. D’Elia E, Gori M, Grosu A, Iorio A, et al. An unexpected case of recurrence of pulmonary embolism in a patient recovered from COVID19 in full regimen dose of direct oral anticoagulant drug. BMC Pulm Med. 2021;21(1):102.

50. Valencia-Manrique JC et al. A case of saddle pulmonary embolism in the recovery phase of COVID-19 infection. Am J Respir Crit Care Med. 2021.

51. Kano M, Cardi T, Manzak H, et al. Delayed pulmonary embolism after COVID-19 pneumonia: a case report. E H J-Case reports. 2020;4(6):1–4.

52. Sadaf A, Smitha M, et al. Acute cor pulmonale from saddle pulmonary embolism in a patient with previous COVID-19: should we prolong prophylactic anticoagulation? Int J Infect Dis. 2020;97:e299–302.

53. Kaur G et al. Post-acute pulmonary embolism in COVID-19 pneu- monia. J Am Coll Cardiol. 2021;2796.

54. Baird A, Bokhari S, Fabrizio C, Hickey G, Risbano M. Thromboembolic disease: one of many common post-COVID-19 complications coming soon to an emergency room near you. Chest. 2021;160(4):A2240–1.

55. Vechi HT, Maia LR, Alves M. Late acute pulmonary embolism after mild coronavirus disease 2019 (COVID-19): a case series. Rev Inst Med Trop Sao Paulo. 2020;62:e63.

56. Pop C, Ferent I. High D-dimer values and post-discharge acute pulmonary embolism in young patients with COVID-19: a case series. SNJ Med. 2021;16(1):e85–90.

57. Beckman M, Nyrén S, Kistner A. A case report of widespread pulmonary embolism in a middle-aged male seven weeks after asymptomatic suspected COVID 19 infection. Thromb J. 2020;18:19.

58. Overstad S, Tjonnfjord E, Garabet L, et al. Venous thromboembolism and coronavirus disease 2019 in an ambulatory care setting - a report of 4 cases. Thromb Res. 2020;194:e116–8.

59. Maloumbi P, Hassouni A, Ibara-Onguema JR, et al. Late pulmonary embolism in a patient with non-severe COVID-19: case report, value of antithrombotic prophylaxis and literature review. Pan Afr Med J. 2021;38:e185.

60. Kuroyi M, Pavelka E, Omid S, et al. Late-onset pulmonary embolism in young male otherwise healthy COVID-19 patients. Eur J Clin Microbiol Infect Dis. 2021;40(3):e633–5.

61. Rahimzadeh M, and Pooprasert P. Pulmonary embolism in a post covid-19 patient - a case report. The Physician. 2020;6(1)
62. Deutch MR et al. Pulmonary embolism after discharge for COVID-19: A report of two cases. JRSM Cardiovasc Dis. 2021;10:20480040211034998.

63. De Pace D, Ariotti S, Persamieri S, Patti G, Lupi A. Unexpected pulmonary embolism late after recovery from mild COVID-19. EJCRIM. 2021;8

64. Barnawi, Ruba M, et al. “Extensive pulmonary embolism following mild COVID-19 pneumonia.” Cureus. 2022;vol. 14,1 e21436

65. Amaqdouf Saïda, et al. Massive pulmonary embolism complicating mild Covid 19 pneumonia: successful systemic thrombolysis using rt-PA in an elderly patient: a case report. Annals of medicine and surgery. 2012;73:103090.

66. Sitani Keerti, et al. Pulmonary embolism as post-COVID-19 sequelae: role of lung perfusion scintigraphy. Ind J Nucl. 2021;36(4):455–6.

67. Takeshita Hidenori, et al. Pulmonary embolism after dexamethasone treatment for COVID-19: a case report. BMC Infec Dis. 2022;22(1):277.

68. Tomasz Czerski, et al. Late pulmonary embolism in a patient with mild COVID-19. An association with reinfection and the instituted treatment. Folia Cardiologica. 2022;17(3):187–90.

69. Chan KH, Lim SL, Shaaban H, Guron G, Slim J. Persistent hypercoagulable state in COVID-19: a case series of COVID-19 associated pulmonary embolism. J Glob Infect Dis. 2021;13(1):38–41.

70. Oflar E, Caglar FN. Pulmonary embolism after successful COVID-19 treatment. Int J Cardiovasc Acad. 2020;6:137–9.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.